Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 197.05M | 200.45M | 193.01M | 164.04M | 127.95M | 92.84M |
Gross Profit | 108.25M | 111.11M | 109.43M | 100.97M | 79.14M | 51.71M |
EBITDA | -9.35M | -10.03M | -4.41M | 9.54M | 10.40M | 15.37M |
Net Income | -11.25M | -6.02M | -12.15M | 2.58M | 4.42M | 19.41M |
Balance Sheet | ||||||
Total Assets | 482.60M | 499.50M | 494.46M | 519.48M | 463.70M | 219.98M |
Cash, Cash Equivalents and Short-Term Investments | 265.61M | 277.86M | 262.41M | 341.15M | 364.62M | 165.23M |
Total Debt | 7.45M | 17.02M | 14.14M | 18.09M | 0.00 | 2.77M |
Total Liabilities | 102.97M | 103.76M | 101.39M | 93.93M | 56.90M | 236.01M |
Stockholders Equity | 379.62M | 395.74M | 393.06M | 425.30M | 406.46M | -16.03M |
Cash Flow | ||||||
Free Cash Flow | 17.54M | 21.85M | 454.00K | -22.10M | 266.00K | 13.61M |
Operating Cash Flow | 21.30M | 25.38M | 5.28M | -12.23M | 4.63M | 15.16M |
Investing Cash Flow | -67.77M | -82.97M | -93.89M | -55.91M | -20.99M | -1.55M |
Financing Cash Flow | -28.98M | -15.82M | -41.81M | 5.51M | 213.56M | 122.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $430.64M | ― | -2.91% | ― | -1.86% | -2.01% | |
52 Neutral | $7.45B | 0.30 | -61.93% | 2.28% | 16.62% | 1.04% | |
51 Neutral | $229.87M | ― | -44.97% | ― | 21.06% | -99.70% | |
51 Neutral | $229.87M | ― | -44.97% | ― | 21.06% | -99.70% | |
50 Neutral | $188.36M | ― | 271.41% | ― | 85.03% | 53.73% | |
50 Neutral | $188.36M | ― | 271.41% | ― | 85.03% | 53.73% | |
47 Neutral | $464.90M | ― | -29.16% | ― | 25.77% | 49.44% | |
47 Neutral | $464.90M | ― | -29.16% | ― | 25.77% | 49.44% | |
47 Neutral | $179.66M | ― | -52.87% | ― | -4.16% | 12.79% | |
47 Neutral | $179.66M | ― | -52.87% | ― | -4.16% | 12.79% | |
46 Neutral | $441.12M | ― | -177.29% | ― | -23.99% | -100.40% | |
46 Neutral | $441.12M | ― | -177.29% | ― | -23.99% | -100.40% |
On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.
The most recent analyst rating on (CTKB) stock is a Buy with a $8.25 price target. To see the full list of analyst forecasts on Cytek Biosciences stock, see the CTKB Stock Forecast page.